Loading clinical trials...
Loading clinical trials...
An Open-label, Single-arm Phase II Safety Study of Nivolumab in Participants With Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed During or After Receiving at Least One Prior Systemic Regimen (CheckMate 907: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 907)
Conditions
Interventions
Nivolumab
Locations
17
United States
Alabama Oncology
Birmingham, Alabama, United States
Los Angeles Hematology Oncology Medical Group
Los Angeles, California, United States
St Vincent Frontier Cancer Center
Billings, Montana, United States
Broome Oncology
Johnson City, New York, United States
Guthrie Medical Group Sayre
Sayre, Pennsylvania, United States
Local Institution - 0015
Kingston, Ontario, Canada
Start Date
June 2, 2017
Primary Completion Date
February 16, 2021
Completion Date
March 14, 2022
Last Updated
December 5, 2022
NCT07431827
NCT06758401
NCT06427941
NCT07164313
NCT06253871
NCT07361497
Lead Sponsor
Bristol-Myers Squibb
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions